HLA-allele matched unrelated donors compared to HLA-matched sibling donors: role of cell source and disease risk category

Biol Blood Marrow Transplant. 2010 Oct;16(10):1382-7. doi: 10.1016/j.bbmt.2010.03.024. Epub 2010 May 4.

Abstract

To determine whether the risks of allogeneic transplantation are different when the donor is a fully matched unrelated donor (MUD; based on 10/10 HLA alleles) compared to an HLA-identical sibling, we performed a retrospective analysis of 1448 patients with high-risk or advanced hematologic malignancies given T-replete grafts after myeloablative conditioning. No statistically significant differences were found between recipients of a matched sibling donor (MSD) and 10/10 MUD in survival, disease-free survival (DFS), and nonrelapse mortality (NRM) for patients with high-risk disease or those given bone marrow as a graft source. However, for patients with intermediate-risk disease receiving peripheral blood grafts, we observed higher NRM and lower overall survival (OS) in the 10/10 MUD group compared to the MSD cohort. Graft-versus-host disease (GVHD) was higher in the MUD group compared to the MSD group. These results suggest that if a patient has high-risk disease and an MSD is not available, selection of an HLA-allele-matched MUD may provide similar OS and DFS, and therefore lack of an MSD in and of itself should not preclude such a patient from undergoing transplantation. However, for patients with intermediate-risk disease, transplantation with peripheral blood from a 10/10 MUD is associated with lower survival than an MSD.

Publication types

  • Comparative Study
  • Research Support, N.I.H., Extramural

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Bone Marrow Transplantation* / statistics & numerical data
  • Child
  • Child, Preschool
  • Disease-Free Survival
  • Female
  • Graft vs Host Disease / epidemiology
  • Graft vs Host Disease / etiology
  • HLA Antigens / analysis*
  • Hematologic Neoplasms / mortality
  • Hematologic Neoplasms / surgery
  • Humans
  • Infant
  • Kaplan-Meier Estimate
  • Living Donors*
  • Male
  • Middle Aged
  • Myeloablative Agonists / therapeutic use
  • Organ Specificity
  • Peripheral Blood Stem Cell Transplantation* / statistics & numerical data
  • Proportional Hazards Models
  • Retrospective Studies
  • Risk
  • Siblings
  • Transplantation Conditioning
  • Treatment Outcome
  • Young Adult

Substances

  • HLA Antigens
  • Myeloablative Agonists